| Name | Title | Contact Details |
|---|---|---|
Clark Bowers |
Associate General Counsel | Profile |
Christopher Moore |
Assistant General Counsel | Profile |
Stephen Huntsman |
Chief Compliance Officer | Profile |
Shoreline Family Chiropractic is a West Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Curaleaf (CSE: CURA) is a leading vertically integrated cannabis operator in the United States. Headquartered in Wakefield, Massachusetts, Curaleaf is located in 10 states and owns and operates 26 dispensaries, 10 cultivation sites and 9 processing sites with a focus on highly populated, limited license states, including Florida, Massachusetts, New Jersey and New York. Here at Curaleaf, we leverage our extensive research and development capabilities to distribute cannabis products in multiple formats with the highest standard for safety, effectiveness, consistent quality and customer care. We are committed to being the industry`s leading resource in education and advancement through research and advocacy, and our Florida operations were the first in the cannabis industry to receive the Safe Quality Food certification under the Global Food Safety Initiative, setting a new standard of excellence. Our Curaleaf network of operating companies collectively employs a national workforce of over 500 people. Plans for additional growth are actively in place.
Labopharm Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Labopharm Inc. is based in Laval, QC. You can find more information on Labopharm Inc. at www.labopharm.com
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Terms Of Use Please be aware that when engaging with the City of Melbourne, Florida, through its social media pages, you are agreeing to the following terms of use: 1.) The Citys social media sites are not monitored at all times. Do NOT use thes...